JT001 (VV116) for the Treatment of COVID-19

Mild to Moderate COVID-19 Clinical Trial

Official title: A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of JT001 (VV116) in Participants With Mild to Moderate COVID-19

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) in participants with mild to moderate COVID-19.

Clinical Trial Description

Screening Interested participants will sign the appropriate informed consent form (ICF) prior to completion of any study procedures.

The investigator will review symptoms and other non-invasive inclusion and exclusion criteria prior to any invasive procedures. If the participant is eligible after this review, then the site will perform the invasive procedures to confirm eligibility.

Treatment and Assessment

This is the general sequence of events during the 28-day treatment and assessment period:

Complete baseline procedures and samples collection； Participants are randomized to experimental arm or placebo arm； Participants receive study intervention (Q12H X 5 days)； Complete all safety monitoring； Complete all efficacy data collection； Blood samples collection ;

Related Conditions & MeSH terms

• COVID-19
• Mild to Moderate COVID-19

• NCT number: NCT05582629
• Study type: Interventional
• Source: Shanghai Vinnerna Biosciences Co., Ltd.
• Status: Completed
• Phase: Phase 3
• Start date: October 21, 2022
• Completion date: February 14, 2023